Ubs Group Ag Sio Gene Therapies Inc. Transaction History

Ubs Group Ag

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 08, 2023	BUY	$0.28 - $0.44 $21,160 - $33,252	75,573 Added 1669.38%	80,100 $35,000
Q3 2022 Nov 10, 2022	SELL	$0.28 - $0.41 $14,280 - $20,910	-51,002 Reduced 91.85%	4,527 $1,000
Q2 2022 Aug 10, 2022	BUY	$0.25 - $0.73 $13,882 - $40,536	55,529 New	55,529 $20,000
Q1 2022 May 16, 2022	SELL	$0.55 - $1.47 $11,337 - $30,301	-20,613 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$1.29 - $2.36 $26,590 - $48,646	20,613 New	20,613 $26,000
Q2 2021 Aug 13, 2021	SELL	$2.07 - $2.89 $85,905 - $119,935	-41,500 Closed	0 $0
Q1 2021 May 12, 2021	BUY	$2.34 - $3.44 $75,111 - $110,420	32,099 Added 341.44%	41,500 $108,000
Q4 2020 Feb 11, 2021	BUY	$1.91 - $5.63 $17,955 - $52,927	9,401 New	9,401 $26,000

147K

Ticker SIOX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,975,200
Description
Sio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical S...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.